Drug ID:Drug7
Drug Name:PYRIDINE
CID:1049
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NULL
Molecular Formula:C5H5N
Molecular Weight:79.1 g/mol
Isomeric SMILES:C1=CC=NC=C1
Synonyms:PYRIDINE; Azabenzene; 110-86-1; Pyridin; Piridina; Pirydyna; RCRA waste number U196; Caswell No. 717; NCI-C55301; FEMA No. 2966
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt50 1049 Pyridine 211 ALAS1 Rattus norvegicus (Norway rat) 10413312 Pyridine results in increased activity of ALAS1 protein
dt51 1049 Pyridine 942 CD86 Homo sapiens (human) 19665512 Pyridine results in increased expression of CD86 protein
dt52 1049 Pyridine 1543 CYP1A1 Homo sapiens (human) 12147272 CYP2E1 protein promotes the reaction [pyridine results in increased expression of CYP1A1 mrna]|dimethyl sulfoxide inhibits the reaction [CYP2E1 protein promotes the reaction [pyridine results in increased expression of CYP1A1 mrna]]
dt53 1049 Pyridine 1543 CYP1A1 Homo sapiens (human) 11849738 Pyridine results in increased activity of CYP1A1 protein
dt54 1049 Pyridine 1543 CYP1A1 Mus musculus (house mouse) 7511897 Pyridine results in increased expression of CYP1A1 mrna|pyridine results in increased activity of CYP1A1 protein|pyridine results in increased expression of CYP1A1 protein
dt55 1049 Pyridine 1543 CYP1A1 Rattus norvegicus (Norway rat) Pyridine results in increased activity of CYP1A1 protein|pyridine results in increased expression of CYP1A1 protein
dt56 1049 Pyridine 1543 CYP1A1 Rattus norvegicus (Norway rat) Pyridine results in increased expression of CYP1A1 mRNA
dt57 1049 Pyridine 1544 CYP1A2 Rattus norvegicus (Norway rat) Pyridine results in increased activity of CYP1A2 protein|pyridine results in increased expression of CYP1A2 protein
dt58 1049 Pyridine 1544 CYP1A2 Rattus norvegicus (Norway rat) Pyridine results in increased expression of CYP1A2 mRNA
dt59 1049 Pyridine 24300 Cyp2b1 Mus musculus (house mouse) 7511897 Pyridine results in increased expression of CYP2B1 protein

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
ISRCTN23541842 The auxiliary diagnostic value of fissured tongue on axial and peripheral joint dysfunction in Ankylosing Spondylitis Not Available Not Recruiting Zhejiang University Of Chinese Medicine Ankylosing spondylitis Musculoskeletal Diseases … Participants are screened and undergo a clinical … Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

[A case of ulcerative colitis with mesalazine intolerance complicated with agra…

PMID: 37690832
Year: 2023
Relationship Type: Association Score: 9.5

A 73-year-old woman developed ulcerative colitis with mesalazine intolerance a year ago. She relapsed 10 months later. Although she was in clinical r…

A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-…

PMID: 36791618
Year: 2023
Relationship Type: Treatment Score: 9.5

As an ideal anti-inflammatory target, cyclin-dependent kinase 8 (CDK8) has gradually attracted the attention of researchers. CDK8 inhibition up-regul…

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors

PMID: 32527540
Year: 2020
Relationship Type: Association Score: 9.5

Small molecule JAK inhibitors have been demonstrated efficacy in rheumatoid arthritis, inflammatory bowel disease, and psoriasis with the approval of…

Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine…

PMID: 21208525
Year: 2010
Relationship Type: Treatment Score: 9.1

Sulfasalazine salicylazosulfapyridine (SASP), consisting of 5-aminosalicylic acid bound to sulfapyridine by a diazo bond, is an effective drug in th…

Therapeutic potential of a novel pyrazolyl-pyridine derivative in the treatment…

PMID: 39157857
Year: 2024
Relationship Type: Treatment Score: 6.5

Aim: Investigating a novel compound, DMPNP, for treating colitis in mice, a key issue in inflammatory bowel diseases (IBD).Methods: Mice with induced…

A Structure-Based Design Strategy with Pyrazole-Pyridine Derivatives Targeting …

PMID: 38861376
Year: 2024
Relationship Type: Association Score: 6.5

Novel Thienopyridines as RIPK2 Inhibitors for Treating Inflammatory Bowel Disea…

PMID: 33335655
Year: 2020
Relationship Type: Association Score: 6.5

Synthesis and biological evaluation of pyridine-linked indanone derivatives: Po…

PMID: 29910080
Year: 2018
Relationship Type: Treatment Score: 6.3

Comment in Inflamm Bowel Dis. 2019 Mar 14;25(4):e40-e41. BACKGROUND: Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by …

Iodobenzene diacetate (IBD) catalyzed an quick oxidative aromatization of Hantz…

PMID: 22296993
Year: 2012
Relationship Type: Association Score: 6.1

BACKGROUND: For adolescents and young adults (AYA) with inflammatory bowel disease (IBD), the transition from pediatric to adult care is often chall…

Amelioration of dextran sulfate sodium-induced chronic colitis by sulfasalazine…

PMID: 20823682
Year: 2010
Relationship Type: Association Score: 6.1

BACKGROUND: Inflammatory Bowel Disease is a collective term for two distinct long term conditions: Ulcerative Colitis and Crohn's disease. There is …

On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including…

PMID: 17565369
Year: 2007
Relationship Type: Association Score: 6.1

BACKGROUND: Inflammatory bowel disease (IBD) is a disease of unknown etiology characterized by acute and chronic relapsing inflammation. The most su…

Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and s…

PMID: 16298742
Year: 2005
Relationship Type: Treatment Score: 6.1

BACKGROUND: Phenantroline is a zinc-chelator that inhibits biological activities of matrix metalloproteinases (MMPs). Over-expression of MMPs can ac…

Hypervalent iodine mediated synthesis of 1-aryl/hetryl-1,2,4-triazolo[4,3-a] py…

PMID: 12767604
Year: 2003
Relationship Type: Association Score: 6.1

Over the past years, a number of idiopathic, chronic, inflammatory gastrointestinal diseases have been recognized, which can be distinguished from …

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its advers…

PMID: 12186410
Year: 2002
Relationship Type: Adverse Effect Score: 6.1

A genetic component in the etiology of inflammatory bowel disease (IBD) has clearly been demonstrated by epidemiological and genetic linkage studies…

Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualitie…

PMID: 2907823
Year: 1988
Relationship Type: Association Score: 6.1

OBJECTIVES: Perianal Crohn's disease (CD) affects around one-quarter of CD patients and represents a distinct disease phenotype. The objective of th…

Inhibition of colitis by ring-modified analogues of 6-acetamido-2,4,5-trimethyl…

PMID: 32745758
Year: 2020
Relationship Type: Treatment Score: 5.5

6-Aminopyridin-3-ol scaffold has shown an excellent anti-inflammatory bowel disease activity. Various analogues with the scaffold were synthesized in…